Chad Therapeutics announces sales results.CHATSWORTH, Calif.--(BUSINESS WIRE)--April 14, 1997--Chad Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Inc. (ASE (Adaptive Server Enterprise) A relational DBMS from Sybase that runs on Windows NT/2000, Linux and a variety of Unix platforms. ASE is a comprehensive and robust data management product with a long history dating back to the late 1980s. :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ), producer and distributor of oxygen- conserving devices and portable oxygen systems used by pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e) 1. pertaining to the lungs. 2. pertaining to the pulmonary artery. pul·mo·nar·y adj. Of, relating to, or affecting the lungs. patients who need supplementary oxygen, Monday announced preliminary sales results for the fourth quarter and fiscal year ended March 31, 1997. Complete audited operating results are expected to be released at the end of May 1997. Sales for the quarter were $5,078,000, a decrease of 2 percent from the same quarter last year. For the year ended March 31, sales rose to $26,162,000, an increase of 28 percent over the previous year. Charles R. Adams
``Moreover, sales to national-chain accounts as well as independent dealers have also been impacted by increased competitive factors and uncertainties regarding potential cuts in Medicare home oxygen reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. which are again being discussed as part of the federal budget process.'' Adams also indicated that international sales during the quarter were down about 14 percent from the previous year, because of factors affecting the company's largest foreign distributor in Europe. Finally, Adams emphasized that while these conditions and uncertainties may continue to influence quarterly comparisons during the next two quarters, Chad remains well positioned in the home oxygen market with its highly efficient and cost-effective products. CONTACT: Chad Therapeutics Inc., Chatsworth Earl L. Yager, 818/882-0883 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion